Soft Tissue Cancer Management: Isolated Limb Infusion for Sarcoma

Area of Science:

• Oncology
• Surgical Oncology
• Medical Oncology

Background:

• Sarcoma is a diverse cancer with nearly 80 subtypes, necessitating tailored treatments.
• Locally advanced soft tissue sarcomas (STS) of the extremities pose significant treatment challenges.
• Amputation is often standard for non-resectable STS, but limb salvage options are being explored.

Purpose of the Study:

• To evaluate isolated limb infusion (ILI) as an alternative treatment for non-resectable locally advanced STS.
• To assess the efficacy of ILI in achieving regional disease control and limb preservation.
• To determine if ILI can improve outcomes for patients with complex STS cases.

Main Methods:

• Retrospective analysis of 10 patients with STS who underwent ILI.
• ILI administered with melphalan and actinomycin in upper or lower extremities.
• Data collected on treatment response, limb salvage, and survival.

Main Results:

• A 78% overall response rate at 6 months was observed.
• Achieved a 100% limb salvage rate in the study cohort.
• Distant metastasis-free survival was longer in responders compared to non-responders.

Conclusions:

• ILI is a viable treatment for regional control and limb preservation in extremity STS.
• Short-term response rates for ILI are encouraging.
• ILI demonstrates good median overall survival in a complex patient group.